Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Impact of Amotosalen/UVA Pathogen Inactivated Platelet Components on Outcomes after Allogeneic Hematopoetic Stem Cell Transplantation: A Single Center Analysis

Andreas S. Buser, MD, Laura Infanti, MD, Andreas Holbro, MD, Joerg Halter, MD, Sabine Gerull, MD, Dominik Heim, MD, Michael Medinger, MD, Dimitrios A. Tsakiris, MD, Johannes Irsch, PhD, Jin-Sying Lin, PhD, Richard J. Benjamin, MD, Laurence Corash, MD, Jakob R. Passweg, MD

Blood (2019) 134 (Supplement_1): 1167.

https://doi.org/10.1182/blood-2019-122330

Published: 2019

Journal Articles

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Zaid Abdel Rahman, MD, Michael G. Heckman, Kevin C. Miller, BS, Patricia Greipp, DO, Matthew R Spiegel, Sharad Khurana, MDMSc, Hassan B. Alkhateeb, MD, Mrinal M Patnaik, MDMBBS, Lisa Z. Sproat, MD, Liuyan Jiang, Vivek Roy, MD, Mark Litzow, MD, Mohamed A Kharfan-Dabaja, MDMBA, William J Hogan, MB, BCh, James M. Foran, MD

Blood (2019) 134 (Supplement_1): 2588.

https://doi.org/10.1182/blood-2019-122068

Published: 2019

Journal Articles

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

Blood (2018) 132 (Supplement 1): 232.

https://doi.org/10.1182/blood-2018-99-116838

Published: 2018

Journal Articles

Reinvestigation of the T-Cell Inactivation Achieved for the Prevention of TA GV HD By 2500 Gy of Gamma Irradiation, a Comparison with Pathogen Reduction

Patricia A Merkel, Hannah E Giclas, Andrew Gibula, Gillian Andersen, Vijaya Knight, Jin-Sying Lin, Grace Castro, Jennifer Green, Adonis Stassinopoulos

Blood (2016) 128 (22): 1455.

https://doi.org/10.1182/blood.V128.22.1455.1455

Published: 2016

Journal Articles

Amotosalen/UVA-Treated Platelet Components Are Efficacious in Massively Transfused Patients

Walter Nussbaumer, MD, Marco Amato, MD, Harald Schennach, MD, Manfred Astl, MD, Chih Yu Chen, Jin-Sying Lin, Richard J. Benjamin, MD PhD

Blood (2016) 128 (22): 2632.

https://doi.org/10.1182/blood.V128.22.2632.2632

Published: 2016

Journal Articles

Treatment Use Study of Platelet Components Treated with Amotosalen and Ultraviolet a Light in Response to Emerging Arboviruses in Puerto Rico - True Study Final Results

Salvador Rico, Susan L. Stramer, PhD, Richard J. Benjamin, MD PhD, Edgardo Cartagena, Axel Arroyo, Nelson Robles, Simon Carlo, L Vera, P Solivan-Ortiz, Norman Huang, Claudia Koontz, Travis Berry, Laurence Corash

Blood (2016) 128 (22): 3844.

https://doi.org/10.1182/blood.V128.22.3844.3844

Published: 2016

Journal Articles

How I treat mycosis fungoides and Sézary syndrome

Sean Whittaker, Richard Hoppe, H. Miles Prince

Blood (2016) 127 (25): 3142–3153.

https://doi.org/10.1182/blood-2015-12-611830

Published: 2016

Journal Articles

Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes)

Koji Sasaki, Elias Jabbour, MD, Naveen Pemmaraju, MD, Naval G. Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD, Sherry Pierce, BSN, BA, Gautam Borthakur, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 1922.

https://doi.org/10.1182/blood.V124.21.1922.1922

Published: 2014

Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD

Blood (2013) 122 (21): 4820.

https://doi.org/10.1182/blood.V122.21.4820.4820

Published: 2013

Journal Articles

Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance.

Laurence Corash, MD

Blood (2012) 120 (21): 2278.

https://doi.org/10.1182/blood.V120.21.2278.2278

Published: 2012

Journal Articles

Potent Strategy for Treatmet of Gvhd and Autoimmune-Diseased by Infusion of Donor-Typed or Even Third-Party Tolerogenic Dendritic Cells by Psoralen Plus UVA Treatment

Hideaki Maeba, MD, Ryosei Nishimura, MD, PhD, Rie Kuroda, MD, Raita Araki, MD, Shintaro Mase, MD, Yasuhiro Ikawa, MD, PhD, Akihiro Yachie, MD, PhD, Shoichi Koizumi, MD, PhD

Blood (2010) 116 (21): 2777.

https://doi.org/10.1182/blood.V116.21.2777.2777

Published: 2010

Journal Articles

Strong Inhibition of Alloreaction by Newly Generated Tolerogenic Dendritic Cells by Psoralen Plus UVA Treatment.

Hideaki Maeba, MD, Ryosei Nishimura, MD, PhD, Rie Kuroda, MD, Raita Araki, MD, Shintaro Mase, MD, Yasuhiro Ikawa, MD, Akihiro Yachie, MD, PhD, Shoichi Koizumi, MD, PhD

Blood (2009) 114 (22): 3686.

https://doi.org/10.1182/blood.V114.22.3686.3686

Published: 2009

Journal Articles

Ex-Vivo UVA Treated Donor T-Cells for the Induction of Graft Versus Leukemia Effect in Murine Model and Clinical Application

Si mcha Samuel, Lola Weiss, Osnat Hazan, Igor B Resnick, Michael Y. Shapira, MD, Benjamin Gesundheit, Lilane Dray, Reuven Or

Blood (2008) 112 (11): 4618.

https://doi.org/10.1182/blood.V112.11.4618.4618

Published: 2008

Journal Articles

Photochemical Pathogen Inactivation Treatment of Human Plasma (amotosalen + UVA) Has No Major Impact on the Protein expression pattern Assessed by a 2-DIGE Proteomic Assay.

Jean-Pierre Cazenave, MD, PhD, Philippe Ohlmann, Hervé Isola, Christian Gachet, MD

Blood (2008) 112 (11): 1994.

https://doi.org/10.1182/blood.V112.11.1994.1994

Published: 2008

Journal Articles

Comparison of UVA and UVB Induced Lesions in Human Platelets Evaluated in an Animal Model.

Monique P. Gelderman-Fuhrmann, PhD, Jessica L. Lewis, Elisabet K. Tassis, Alex C. Vostal, Jaroslav G. Vostal, M.D., Ph.D.

Blood (2007) 110 (11): 2883.

https://doi.org/10.1182/blood.V110.11.2883.2883

Published: 2007

Journal Articles

An Active Hemovigilance Program Characterizing the Safety Profile of 7,437 Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT™).

J.C. Osselaer, J.P. Cazenave, C. Waller, M. Lambermont, O. Garraud, P. Fabrigli, M. Hidajat, D. Dehenau, L. Barbolla, J.L. Arroyo, R. Tardivel, M. Jacquet, D. Sundin, Lily Lin, L. Corash

Blood (2007) 110 (11): 2894.

https://doi.org/10.1182/blood.V110.11.2894.2894

Published: 2007

Journal Articles

Retention of Thrombin Generation Capacity of Therapeutic Apheresis Plasma Prepared with Amotosalen and UVA Light (INTERCEPT) Pathogen Inactivation.

Jean-Pierre Cazenave, MD, PhD, Pierre Netzer, Simone Schuhler, Catherine Ravanat, PhD, Hervé Isola, Daniel Kientz, MD, Christian Gachet, MD, PhD, Marie-Louise Wiesel, MD

Blood (2007) 110 (11): 4027.

https://doi.org/10.1182/blood.V110.11.4027.4027

Published: 2007

Journal Articles

The Pathogen Inactivation of Platelets: Studies of the Possible Mechanisms of the Platelet Dysfunction Seen Following Photochemical Treatment.

Adam D. Pyke, BA, MSc, Morris A. Blajchman, MD, FRCP(C)

Blood (2006) 108 (11): 581.

https://doi.org/10.1182/blood.V108.11.581.581

Published: 2006

Journal Articles

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Markus M. Mueller, MD, Hans-Ulrich Pfeiffer, Margaret Rheinschmidt, PhD, Bernd Poetzsch, MD, PhD, Johannes Oldenburg, MD, PhD, Laurence Corash, MD, PhD, Erhard Seifried, MD, PhD, Reinhard Henschler, MD, PhD

Blood (2006) 108 (11): 942.

https://doi.org/10.1182/blood.V108.11.942.942

Published: 2006

Journal Articles

Routine Use of Platelet Components Prepared with Photochemical Treatment (INTERCEPT Platelets™): Impact on Clinical Outcomes and Resources.

Jean Claude Osselaer, MD, JD, Chantal Doyen, MD, Natalie Messe, Maryse Van Hooydonk, RN, Michele Jacquet, MS, Anne Sonnet, MD, Andre Bosly, MD, PhD, Jocelyne Flament, MD, Laurence Corash, MD

Blood (2005) 106 (11): 429.

https://doi.org/10.1182/blood.V106.11.429.429

Published: 2005

NARROW

Impact of Amotosalen/UVA Pathogen Inactivated Platelet Components on Outcomes after Allogeneic Hematopoetic Stem Cell Transplantation: A Single Center Analysis

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

Reinvestigation of the T-Cell Inactivation Achieved for the Prevention of TA GV HD By 2500 Gy of Gamma Irradiation, a Comparison with Pathogen Reduction

Amotosalen/UVA-Treated Platelet Components Are Efficacious in Massively Transfused Patients

Treatment Use Study of Platelet Components Treated with Amotosalen and Ultraviolet a Light in Response to Emerging Arboviruses in Puerto Rico - True Study Final Results

How I treat mycosis fungoides and Sézary syndrome

Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes)

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance.

Potent Strategy for Treatmet of Gvhd and Autoimmune-Diseased by Infusion of Donor-Typed or Even Third-Party Tolerogenic Dendritic Cells by Psoralen Plus UVA Treatment

Strong Inhibition of Alloreaction by Newly Generated Tolerogenic Dendritic Cells by Psoralen Plus UVA Treatment.

Ex-Vivo UVA Treated Donor T-Cells for the Induction of Graft Versus Leukemia Effect in Murine Model and Clinical Application

Photochemical Pathogen Inactivation Treatment of Human Plasma (amotosalen + UVA) Has No Major Impact on the Protein expression pattern Assessed by a 2-DIGE Proteomic Assay.

Comparison of UVA and UVB Induced Lesions in Human Platelets Evaluated in an Animal Model.

An Active Hemovigilance Program Characterizing the Safety Profile of 7,437 Platelet Transfusions Prepared with Photochemical Treatment (INTERCEPT™).

Retention of Thrombin Generation Capacity of Therapeutic Apheresis Plasma Prepared with Amotosalen and UVA Light (INTERCEPT) Pathogen Inactivation.

The Pathogen Inactivation of Platelets: Studies of the Possible Mechanisms of the Platelet Dysfunction Seen Following Photochemical Treatment.

Effects of Pathogen Inactivation Using Amotosalen-UVA on Coagulation Parameters in Apheresis and Whole Blood Derived Frozen Plasma in a Large Blood Bank Setting.

Routine Use of Platelet Components Prepared with Photochemical Treatment (INTERCEPT Platelets™): Impact on Clinical Outcomes and Resources.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only